The international melatonin institute
Under the direction of doctors Darío Acuña Castroviejo and Germaine Escames—physiology professors in the Faculty of Medicine at the University of Granada—the International Melatonin Institute (IiMEL) is an international reference model in the field of melatonin research.
Dr. Acuña-Castroviejo, professor of Physiology, and Dr. Escames, tenured adjunct lecturer in Physiology, have more than 30 years’ experience in the study of the physiology of melatonin, its mechanisms of action, and its application in the field of anti-aging medicine, as well as in various pathologies such as insomnia, fibromyalgia, chronic fatigue, epilepsy, Parkinson’s and Alzheimer’s diseases, sepsis, muscular dystrophies, diabetes, and more generally in combination with oxidative stress and inflammation associated, or otherwise, with chronopathologies.
A recent clinical application of melatonin is its use to alleviate the adverse effects of radio- and chemotherapy. In contrast, melatonin has long been studied in relation to alterations in circadian rhythms such as sleep and wakefulness, and its relationship to pathologies derived from exposure to electromagnetic fields, which are applications currently of great interest.
Regarding the many studies carried out on melatonin by IiMEL, the following results stand out as its main milestones:
1985: the anticonvulsant effects of melatonin, mediated by its regulation of cerebral GABA and glutamate receptors, and its clinical utility in childhood epilepsies was demonstrated.
1993: melatonin’s nuclear receptor was characterised, thus explaining the genomic actions of this hormone. These receptors have been described in different tissues, and so new melatonin signalling pathways were identified throughout the body.
1994: the antioxidant properties of melatonin in different experimental models, and its clinical applications started to be studied.